Updates are available Correction dated 2022-07-15
Click to view Correction: https://doi.org/10.1038/s43018-022-00420-y
-
Authors
Walle, Thomas http://orcid.org/0000-0003-4835-955X
Bajaj, Sunanjay
Kraske, Joscha A. http://orcid.org/0000-0002-8567-6020
Rösner, Thomas
Cussigh, Christiane S.
Kälber, Katharina A.
Müller, Lisa Jasmin
Strobel, Sophia Boyoung
Burghaus, Jana
Kallenberger, Stefan M.
Stein-Thöringer, Christoph K.
Jenzer, Maximilian
Schubert, Antonia
Kahle, Steffen
Williams, Anja
Hoyler, Birgit
Zielske, Lin
Skatula, Renate
Sawall, Stefanie
Leber, Mathias F.
Kunes, Russell Z.
Krisam, Johannes
Fremd, Carlo
Schneeweiss, Andreas
Krauss, Jürgen
Apostolidis, Leonidas
Berger, Anne Katrin
Haag, Georg M.
Zschäbitz, Stefanie
Halama, Niels http://orcid.org/0000-0003-0344-6027
Springfeld, Christoph
Kirsten, Romy
Hassel, Jessica C.
Jäger, Dirk
Cussigh, Christiane S.
Kälber, Katharina A.
Abdelrahim, Omar
Busch, Elena
Derigs, Patrick
Dischinger, Katharina
Mitri, Fouad
Schmidt, Kerstin
Bhatti, Irfan A.
Grün, Barbara
Hohmann, Nicolas
Woydack, Lena
Zhang, Xin-Wen
Ferber, Dyke
Mock, Andreas
Pompecki, Tillmann
Schank, Timo
Fremd, Carlo
Haag, Georg M.
Halama, Niels
Kirsten, Romy
Hassel, Jessica C.
Jäger, Dirk
Ungerechts, Guy
,
-
Funding
Funding for this research was provided by:
DKFZ Clinician Scientist ProgramCanVirex GmbH
DKFZ Clinician Scientist Program
- License Information
-
More Information
Article History
Received: 24 December 2021
Accepted: 16 May 2022
First Online: 17 June 2022
Change Date: 15 July 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s43018-022-00420-y
Competing interests
: T.W. reports previous and current stock ownership of various pharmaceutical companies manufacturing SARS-CoV-2 vaccines and diagnostics including BionTech, Astra Zeneca and Roche. T.W. also reports research support from CanVirex, a spin-off company of the Heidelberg University Hospital developing viral vector-based immunotherapies and vaccines (financial support for blood sampling materials). G.U. is founder and current CMO/CSO of CanVirex, Basel, Switzerland. G.M.H. reports consulting or advisory roles (unrelated) at Bristol-Myers Squibb, MSD Sharp & Dohme, Lilly, Novartis and Daiichi Sankyo; honoraria (unrelated) from Servier, MSD Sharp & Dohme, Lilly, Targos, Bristol-Myers Squibb, IOMEDICO and MCI Conventions; research funding (unrelated) from Nordic Pharma, Taiho Pharmaceutical, MSD Sharp & Dohme, Janssen, Astra Zeneca and IKF Klinische Krebsforschung Frankfurt; and travel/accommodations (unrelated) from Bristol-Myers Squibb, Lilly, Servier and MSD Sharp & Dohme. All other authors declare no competing interests.
